Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Area of Science:

• Cardiovascular Research
• Hypertension Pathophysiology
• Surgical Models

Background:

• Renal sympathetic denervation (RDN) shows promise for managing hypertension, but its precise regulatory mechanisms require further investigation.
• Existing animal models for RDN are complex, hindering detailed study of hypertension's underlying pathology.
• A simplified, standardized RDN model in mice is needed to advance research in this field.

Purpose of the Study:

• To develop and validate a simple, practical, and reproducible mouse model for renal sympathetic denervation (RDN).
• To assess the efficacy of the modified RDN model in controlling Angiotensin II-induced hypertension.
• To evaluate the impact of RDN on cardiac hypertrophy and renal artery integrity.

Main Methods:

• Establishment of a mouse model using osmotic mini-pumps for Angiotensin II infusion.
• Performance of a modified phenol-based renal sympathetic denervation (RDN) procedure on bilateral renal arteries.
• Monitoring of blood pressure weekly for 21 days post-RDN and histological analysis of renal arteries, aorta, and heart.

Main Results:

• The developed RDN model successfully controlled hypertension induced by Angiotensin II.
• Histological examination confirmed effective denervation of renal sympathetic nerves without causing renal artery damage.
• The RDN procedure led to a significant alleviation of cardiac hypertrophy in the treated mice.

Conclusions:

• A simple, repeatable, and standardized mouse model for renal sympathetic denervation (RDN) has been successfully established.
• This model effectively controls hypertension and mitigates cardiac hypertrophy, offering a valuable tool for research.
• The modified RDN technique facilitates the study of hypertension's pathobiology and pathophysiology.